Oxford Immunotec Global (NASDAQ:OXFD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “

Several other brokerages have also issued reports on OXFD. Cowen reaffirmed a “buy” rating and set a $15.00 target price on shares of Oxford Immunotec Global in a research report on Monday. BTIG Research started coverage on Oxford Immunotec Global in a research report on Thursday, September 28th. They set a “buy” rating and a $21.00 target price for the company. BidaskClub lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Thursday, January 11th. ValuEngine lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. Finally, Robert W. Baird reaffirmed a “buy” rating and set a $20.00 target price on shares of Oxford Immunotec Global in a research report on Wednesday, November 1st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $18.75.

Oxford Immunotec Global (NASDAQ OXFD) opened at $11.59 on Tuesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.30 and a current ratio of 4.72. Oxford Immunotec Global has a 52 week low of $10.81 and a 52 week high of $19.51. The firm has a market capitalization of $297.34, a price-to-earnings ratio of -5.77 and a beta of -0.09.

Oxford Immunotec Global (NASDAQ:OXFD) last issued its quarterly earnings data on Tuesday, October 31st. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. Oxford Immunotec Global had a negative return on equity of 38.42% and a negative net margin of 45.74%. equities research analysts anticipate that Oxford Immunotec Global will post -2.16 earnings per share for the current year.

In other news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the completion of the sale, the director now directly owns 17,778 shares of the company’s stock, valued at approximately $237,336.30. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 8.11% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Voya Investment Management LLC increased its holdings in Oxford Immunotec Global by 16.0% in the 2nd quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after acquiring an additional 1,845 shares during the last quarter. Alliancebernstein L.P. purchased a new stake in Oxford Immunotec Global in the 2nd quarter worth about $247,000. Asymmetry Capital Management L.P. purchased a new stake in Oxford Immunotec Global in the 2nd quarter worth about $273,000. The Manufacturers Life Insurance Company increased its holdings in Oxford Immunotec Global by 8.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock worth $313,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in Oxford Immunotec Global by 9.1% in the 2nd quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock worth $412,000 after acquiring an additional 2,053 shares during the last quarter. 89.30% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Oxford Immunotec Global (OXFD) Upgraded to “Hold” at Zacks Investment Research” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2018/01/25/oxford-immunotec-global-oxfd-upgraded-to-hold-at-zacks-investment-research.html.

About Oxford Immunotec Global

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.